The Association between the Extent of Late Gadolinium Enhancement and Diastolic Dysfunction in Hypertrophic Cardiomyopathy
Background Diastolic dysfunction in hypertrophic cardiomyopathy (HCM) patients is a frequent, yet poorly understood phenomenon.
Purpose The purpose of this study is to assess the relationship between the myocardial fibrosis and diastolic dysfunction in patients with HCM.
Materials and Methods We retrospectively investigated the impact of the myocardial fibrosis, as assessed by the extent of late gadolinium enhancement (LGE-%) on cardiac magnetic resonance imaging (CMRI), on diastolic dysfunction in 110 patients with HCM. The diastolic dysfunction was evaluated by the left atrial (LA) volume index measured on CMRI and lateral septal E/E′ ratio calculated on echocardiography.
Results : There was a moderate correlation between the LGE-% and LA volume (r = 0.59, p < 0.0001). The logistic regression model of LGE-%, mitral regurgitation, and total left ventricular mass that investigated the independent predictors of LA volume identified LGE-% as the only independent parameter associated with the LA volume index (β = 0.30, p = 0.003). No correlation was observed between the LGE-% and E/E′(r = 0.24, p = 0.009).
Conclusions Myocardial fibrosis in HCM patients is associated with a chronic diastolic burden as represented by increased LA volume. However, the fibrosis does not influence the E/E′ ratio, which is a well-known parameter of ventricular relaxation, restoring forces, and filling pressure.
28. Juli 2021 (online)
© 2021. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287 (10) 1308-1320
- 2 Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995; 92 (07) 1680-1692
- 3 Elliott PM, Anastasakis A, Borger MA. et al. Authors/Task Force members. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC. Eur Heart J 2014; 35 (39) 2733-2779
- 4 Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008; 117 (03) 429-439
- 5 Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. J Am Coll Cardiol 2008; 51 (07) 679-689
- 6 Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res 2004; 94 (12) 1533-1542
- 7 Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007; 116 (23) 2702-2708
- 8 Rakowski H, Carasso S. Quantifying diastolic function in hypertrophic cardiomyopathy: the ongoing search for the holy grail. Circulation 2007; 116 (23) 2662-2665
- 9 Sipola P, Lauerma K, Jääskeläinen P. et al. Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the alpha-tropomyosin gene. Radiology 2005; 236 (03) 815-824
- 10 Pons-Lladó G, Carreras F, Borrás X, Palmer J, Llauger J, Bayés de Luna A. Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Am J Cardiol 1997; 79 (12) 1651-1656
- 11 Pennell DJ. Cardiovascular magnetic resonance. Circulation 2010; 121 (05) 692-705
- 12 Reichek N, Gupta D. Hypertrophic cardiomyopathy: cardiac magnetic resonance imaging changes the paradigm. J Am Coll Cardiol 2008; 52 (07) 567-568
- 13 Nagueh SF, Smiseth OA, Appleton CP. et al. Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 17 (12) 1321-1360
- 14 Cerqueira MD, Weissman NJ, Dilsizian V. et al. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105 (04) 539-542
- 15 Hinkle DE, Wiersma W, Jurs SG. Applied Statistics for the Behavioral Sciences 5th ed. Boston, Massachusetts: Houghton Mifflin 2003
- 16 Motoyasu M, Kurita T, Onishi K. et al. Correlation between late gadolinium enhancement and diastolic function in hypertrophic cardiomyopathy assessed by magnetic resonance imaging. Circ J 2008; 72 (03) 378-383
- 17 Nucifora G, Muser D, Gianfagna P, Morocutti G, Proclemer A. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis. Int J Cardiovasc Imaging 2015; 31 (08) 1603-1610
- 18 Rathi VK, Biederman RWW. Expanding role of cardiovascular magnetic resonance in left and right ventricular diastolic function. Heart Fail Clin 2009; 5 (03) 421-435
- 19 Ellims AH, Iles LM, Ling LH, Hare JL, Kaye DM, Taylor AJ. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson 2012; 14: 76
- 20 Yang H, Woo A, Monakier D. et al. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr 2005; 18 (10) 1074-1082
- 21 Gersh BJ, Maron BJ, Bonow RO. et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58 (25) e212-e260
- 22 Choi DS, Ha JW, Choi B. et al. Extent of late gadolinium enhancement in cardiovascular magnetic resonance and its relation with left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Circ J 2008; 72 (09) 1449-1453
- 23 Zhu Y, Park EA, Lee W. et al. Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction. Eur Radiol 2015; 25 (04) 1190-1200
- 24 Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part I, MRI appearances. AJR Am J Roentgenol 2007; 189 (06) 1335-1343
- 25 Kasner M, Westermann D, Steendijk P. et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 2007; 116 (06) 637-647